Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass
about
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomasNew paradigms in translational science research in cancer biomarkersProteomics of ovarian cancer: functional insights and clinical applicationsTowards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studiesPreoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC ConsortiumMUC16 (CA125): tumor biomarker to cancer therapy, a work in progressUse of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk womenTen Important Considerations for Ovarian Cancer ScreeningMALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancerDoes risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis.Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings.Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese womenInflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancersMultianalyte assay systems in the differential diagnosis of ovarian cancer.Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkersEarly detection biomarkers for ovarian cancer.Biomarker testing for ovarian cancer: clinical utility of multiplex assaysAssessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic massAssessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trialClinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal MassDiagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125.Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumorsReflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come.Biomarkers for early detection of ovarian cancer.The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery.Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.Prediction of therapy response in ovarian cancer: Where are we now?The role of biomarkers in the management of epithelial ovarian cancer.HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
P2860
Q26992102-C5B1EC6A-FDCD-4606-B921-EB9EE9718B9FQ27027893-30C8B4CE-3A45-4F3A-9ABC-A592AFE5A46EQ28082632-1A1DA9C8-9052-4A1D-AB7B-BB5FA4AD8CAEQ30414041-133F421E-4635-4988-8165-54A2EDE66DA0Q33624809-6C56018B-7D7C-472D-9A5A-F9955F63F125Q33713506-664B2C61-88F8-4C37-9228-84C5F6EEE912Q33848119-C58BBDEF-FE6C-4C11-AD5D-5E0B72F0A1A0Q33850463-14AE0961-F8DD-44D8-BA79-DF818154A03FQ33883474-769E0816-5D08-49C5-8155-AEE00DC7AE7AQ34308808-9D1AA4C5-89CF-4C6B-ACD3-F4DB292D4CC5Q34391119-09F4913E-AF54-4D5B-BBFE-856E2E4DA246Q34996986-8BF84180-EFE8-4A5F-AD13-1963AEB8096CQ35126762-908A0E21-FA31-4FC1-9B5D-53B11E181ABAQ35677625-2C2227FB-F70A-4E7D-A4F1-2BB87BFD13B1Q35854476-C7CB6733-66E0-41B0-BE3A-C1F5A218B433Q35872796-C44264A4-F840-490B-BE9D-3177991362A6Q36037774-1D798435-A608-4134-BC60-7CD906C6EF48Q36076953-2A046316-5184-49D2-A442-1CF71A1F6902Q36520143-FB012DDE-BE5A-4DEA-AFB7-99D76B8E02CAQ36897149-D4A19318-B0E6-4A41-88A4-8CC4EB6676D9Q36904090-FE3BDD34-4D7E-4F14-B3CA-887963F91B93Q37012893-E5CC6293-DCE6-4061-896E-DBF9441DE2C7Q37053905-CCD649E2-E596-4FFA-8A12-A6D6BD64FEF2Q37111350-07C7E56C-691B-4061-BCD5-AB31F30570A2Q37188163-EBA0466F-FFF3-435D-8A13-D2D53F55EBF0Q37201766-F9856027-A43C-4013-B42B-3F422B685CD3Q37406838-FD34E9FA-258C-4717-95C7-A9E5AE57D7E1Q37643626-F745F254-748C-44D3-8DA8-9B079FE2C98CQ37698104-5A6DBEC7-3877-4E9C-AECF-F9E4075579C6Q37701232-4CAB7A35-9B74-400F-B601-90C7B54FFF1AQ37703442-E5F388F7-BBCA-4D78-A066-DB81A16D59FCQ37729980-B4A79E0E-BB2A-4E58-866B-81AAA74DC9ABQ38087982-256A48BE-7700-4F55-B7B5-E45704281DF1Q38388103-C8DD5C08-CF9B-4929-9500-D92984CEAB26Q38470014-7D0BAD68-3E42-4D69-BBD1-3F261D87539EQ38773416-76A73219-7016-414A-9C3F-BF2432BBB637Q38819035-BE3EBAC5-3932-47C6-B958-1CAFFE614DE3Q39263260-8F0E218F-21FD-455F-A25D-23B4BF47C753Q39281140-6F88B791-AC1E-4F41-A569-3F55E2BFF6A4Q41095997-8B84BA82-6E6F-43EB-B0CF-F09960935FFC
P2860
Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Evaluation of the diagnostic a ...... hm in women with a pelvic mass
@ast
Evaluation of the diagnostic a ...... hm in women with a pelvic mass
@en
type
label
Evaluation of the diagnostic a ...... hm in women with a pelvic mass
@ast
Evaluation of the diagnostic a ...... hm in women with a pelvic mass
@en
prefLabel
Evaluation of the diagnostic a ...... hm in women with a pelvic mass
@ast
Evaluation of the diagnostic a ...... hm in women with a pelvic mass
@en
P2093
P2860
P1476
Evaluation of the diagnostic a ...... hm in women with a pelvic mass
@en
P2093
John J Ball
Lisa M Landrum
M Craig Miller
Paul Disilvestro
Richard G Moore
Steven J Skates
Walter Gajewski
P2860
P304
P356
10.1097/AOG.0B013E318224FCE2
P407
P433
P577
2011-08-01T00:00:00Z